Target intelligence / Profile preview

Dual specificity phosphatase 6 (DUSP6) (DUSP6)

Target
DUSP6
Molecular classification
Enzyme, Phosphatase, Dual-specificity phosphatase
01

Overview

Dual specificity phosphatase 6 (DUSP6), also known as MKP3, is a member of the mitogen-activated protein kinase (MAPK) phosphatase family that specifically inactivates ERK1 and ERK2 (Source: UniProt Q16828). It functions as a feedback regulator of the RAS/ERK pathway, where its expression is often induced by ERK signaling to maintain pathway homeostasis (Source: PubMed 25154351). The kinase-binding domain (KBD) at the N-terminus is critical for substrate recognition and specificity, mediating the interaction with the docking site on ERK (Source: PubMed 11003654). In oncology, DUSP6 is frequently overexpressed in cancers driven by the MAPK pathway, such as pancreatic and lung adenocarcinoma, where it may promote cell survival or contribute to drug resistance (Source: PubMed 28655770). Small molecule inhibitors like BCI (E-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one) target the DUSP6 KBD/catalytic interface to allosterically inhibit its activity, leading to increased ERK phosphorylation and potential anti-tumor effects (Source: PubMed 19114708).

Other names
MKP3Mitogen-activated protein kinase phosphatase 3PYST1Dual specificity protein phosphatase 6
02

Mechanism of action

Allosteric inhibition of the phosphatase activity by binding to the kinase-binding domain or the interface between the KBD and the catalytic domain, preventing the dephosphorylation of ERK1/2.

03

Biological functions

Signal transductionMAPK inactivationCell proliferationCell differentiationApoptosis regulation
04

Disease associations

CancerPancreatic cancerLung cancerMelanomaMetabolic disorders
05

Safety considerations

Potential off-target inhibition of other DUSP family membersSystemic toxicity from MAPK pathway hyperactivationContext-dependent role in tumor suppression vs. promotion
06

Interacting drugs

BCI (E-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one)

1 more in the full profile.

07

Biomarkers

p-ERK levelsDUSP6 mRNA expressionDUSP6 protein levels

Beyond the preview

Go deeper on Dual specificity phosphatase 6 (DUSP6) (DUSP6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dual specificity phosphatase 6 (DUSP6) (DUSP6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call